Clinical Guidelines

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...

By
Caroline Helwick
February 20, 2026
9 min

The ASCO Post

A phase III trial (EPCORE FL-1) demonstrated that the bispecific antibody epcoritamab-bysp combined with rituximab-lenalidomide (R2) significantly reduced disease progression or death by nearly 80% compared to R2 alone in relapsed follicular lymphoma patients. Conducted with 488 patients, results revealed improved progression-free survival, response rates, and durability of response, making epcoritamab-R2 a potential new standard of care. The data showed manageable safety profiles, allowing outpatient administration, which may enhance patient access to treatment.

Original Source(s)

The ASCO Post

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

by Caroline Helwick
February 20, 2026
9 min

Related Content

Fox Chase Cancer Center

Delivering Big Ideas from ASH 2025

At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:

by
February 17, 2026
1 min

Keck Medicine of USC

Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

by
February 13, 2026
12 min

The Pathologist

Smarter Digital Morphology Triage

A diffusion-based approach aims to handle domain shifts, slide variability, and rare cell appearances

January 30, 2026
3 min